<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37290316</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-035X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of infection and public health</Title><ISOAbbreviation>J Infect Public Health</ISOAbbreviation></Journal><ArticleTitle>The estimated disease burden of COVID-19 in Japan from 2020 to 2021.</ArticleTitle><Pagination><StartPage>1236</StartPage><EndPage>1243</EndPage><MedlinePgn>1236-1243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiph.2023.05.025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-0341(23)00180-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To date, it is not fully understood to what extent COVID-19 has burdened society in Japan. This study aimed to estimate the total disease burden due to COVID-19 in Japan during 2020-2021.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We stratify disease burden estimates by age group and present it as absolute Quality Adjusted Life Years (QALYs) lost and QALYs lost per 100,000 persons. The total estimated value of QALYs lost consists of (1) QALYs lost brought by deaths due to COVID-19, (2) QALYs lost brought by inpatient cases, (3) QALYs lost brought by outpatient cases, and (4) QALYs lost brought by long-COVID.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The total QALYs lost due to COVID-19 was estimated as 286,782 for two years, 114.0 QALYs per 100,000 population per year. 71.3% of them were explained by the burden derived from deaths. Probabilistic sensitivity analysis showed that the burden of outpatient cases was the most sensitive factor.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The large part of disease burden due to COVID-19 in Japan from the beginning of 2020 to the end of 2021 was derived from Wave 3, 4, and 5 and the proportion of QALYs lost due to morbidity in the total burden increased gradually. The estimated disease burden was smaller than that in other high-income countries. It will be our future challenge to take other indirect factors into consideration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsuzuki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine &amp; Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: stsuzuki@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beutels</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine &amp; Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect Public Health</MedlineTA><NlmUniqueID>101487384</NlmUniqueID><ISSNLinking>1876-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Disease burden</Keyword><Keyword MajorTopicYN="N">Japan</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ST reports payment for supervising medical articles outside this study from Gilead Sciences, Inc. PB reports grants from Pfizer, GlaxoSmithKline, and the European Commission IMI, unrelated to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37290316</ArticleId><ArticleId IdType="pmc">PMC10210821</ArticleId><ArticleId IdType="doi">10.1016/j.jiph.2023.05.025</ArticleId><ArticleId IdType="pii">S1876-0341(23)00180-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507&#x2013;513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Current status of the novel coronavirus infection and the response of the MHLW. n.d. https://www.mhlw.go.jp/stf/newpage_09290.html (accessed June 1, 2022).</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Information list for local authorities and healthcare facilities: COVID-19 2020. https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00024.html (accessed August 17, 2021).</Citation></Reference><Reference><Citation>Matsunaga N., Hayakawa K., Terada M., Ohtsu H., Asai Y., Tsuzuki S., et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1470</ArticleId><ArticleId IdType="pmc">PMC7543311</ArticleId><ArticleId IdType="pubmed">32986793</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue H. Japanese strategy to COVID-19: How does it work. Glob Health Med. 2020;2:131&#x2013;132. doi: 10.35772/ghm.2020.01043.</Citation><ArticleIdList><ArticleId IdType="doi">10.35772/ghm.2020.01043</ArticleId><ArticleId IdType="pmc">PMC7731332</ArticleId><ArticleId IdType="pubmed">33330791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Information on health and medical consultation n.d. https://www.mhlw.go.jp/stf/covid-19/kenkou-iryousoudan_00006.html (accessed February 23, 2022).</Citation></Reference><Reference><Citation>Yamaguchi S., Okada A., Sunaga S., Kurakawa K.I., Yamauchi T., Nangaku M., et al. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open. 2022;12 doi: 10.1136/bmjopen-2021-060390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-060390</ArticleId><ArticleId IdType="pmc">PMC9058318</ArticleId><ArticleId IdType="pubmed">35466081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono A., Koizumi R., Tsuzuki S., Asai Y., Ishikane M., Kusama Y., et al. Antimicrobial use fell substantially in Japan in 2020&#x2014;The COVID-19 pandemic may have played a role. Int J Infect Dis. 2022 doi: 10.1016/j.ijid.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC8926437</ArticleId><ArticleId IdType="pubmed">35306203</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Cases - Our World in Data n.d. https://ourworldindata.org/covid-cases (accessed February 24, 2022).</Citation></Reference><Reference><Citation>Healthcare in the UK | Coronavirus in the UK n.d. https://coronavirus.data.gov.uk/details/healthcare (accessed December 3, 2022).</Citation></Reference><Reference><Citation>United States - COVID-19 Overview - Johns Hopkins. Johns Hopkins Coronavirus Resource Center n.d. https://coronavirus.jhu.edu/region/united-states (accessed December 3, 2022).</Citation></Reference><Reference><Citation>Idogawa M., Tange S., Nakase H., Tokino T. Interactive web-based graphs of coronavirus disease 2019 cases and deaths per population by country. Clin Infect Dis. 2020;71:902&#x2013;903. doi: 10.1093/cid/ciaa500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa500</ArticleId><ArticleId IdType="pmc">PMC7197615</ArticleId><ArticleId IdType="pubmed">32339228</ArticleId></ArticleIdList></Reference><Reference><Citation>del Rio C., Collins L.F., Malani P. Long-term health consequences of COVID-19. JAMA. 2020 doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K., Asai Y., Matsunaga N., Tsuzuki S., Terada M., Suzuki S., et al. Evaluation of the representativeness of data in the COVID-19 Registry Japan during the first six waves of the epidemic. Glob Health Med. 2022 doi: 10.35772/ghm.2022.01033.</Citation><ArticleIdList><ArticleId IdType="doi">10.35772/ghm.2022.01033</ArticleId><ArticleId IdType="pmc">PMC9420330</ArticleId><ArticleId IdType="pubmed">36119783</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K., et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7 doi: 10.1093/ofid/ofaa507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa507</ArticleId><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39:159&#x2013;167. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N., Zhao Y.-M., Yan W., Li C., Lu Q.-D., Liu L., et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28:423&#x2013;433. doi: 10.1038/s41380-022-01614-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01614-7</ArticleId><ArticleId IdType="pmc">PMC9168643</ArticleId><ArticleId IdType="pubmed">35668159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Miyazato Y., Terada M., Morioka S., Ohmagari N., Beutels P. Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients. Health Qual Life Outcomes. 2022;20:125. doi: 10.1186/s12955-022-02033-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-022-02033-6</ArticleId><ArticleId IdType="pmc">PMC9388960</ArticleId><ArticleId IdType="pubmed">35986269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections n.d. https://covid19.mhlw.go.jp/extensions/public/en/index.html (accessed February 24, 2022).</Citation></Reference><Reference><Citation>National Institute of Population and Social Security Research. Population Statistics 2020. http://www.ipss.go.jp/syoushika/tohkei/Popular/Popular2014.asp?chap=5&amp;title1=%87X%81D%8E%80%96S%81E%8E%F5%96%BD (accessed December 20, 2020).</Citation></Reference><Reference><Citation>Tsuzuki S., Ohmagari N., Beutels P. The burden of isolation to the individual: a comparison between isolation for COVID-19 and for other influenza-like illnesses in Japan. Epidemiol Infect. 2022:150. doi: 10.1017/S0950268821002569. e5-undefined.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268821002569</ArticleId><ArticleId IdType="pmc">PMC8755532</ArticleId><ArticleId IdType="pubmed">36043378</ArticleId></ArticleIdList></Reference><Reference><Citation>Glick H.A., Miyazaki T., Hirano K., Gonzalez E., Jodar L., Gessner B.D., et al. One-year quality of life post&#x2013;pneumonia diagnosis in Japanese adults. Clin Infect Dis. 2021;73:283&#x2013;290. doi: 10.1093/cid/ciaa595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa595</ArticleId><ArticleId IdType="pmc">PMC8282327</ArticleId><ArticleId IdType="pubmed">32447366</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022:13. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S., Abbafati C., Aerts J.G., Al-Aly Z., Ashbaugh C., Ballouz T., et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022 doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustovski F., Colantonio L.D., Galante J., Bardach A., Caporale J.E., Zarate V., et al. Measuring the benefits of healthcare: DALYs and QALYs - does the choice of measure matter? A case study of two preventive interventions. Int J Health Policy Manag. 2017;7:120&#x2013;136. doi: 10.15171/ijhpm.2017.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/ijhpm.2017.47</ArticleId><ArticleId IdType="pmc">PMC5819372</ArticleId><ArticleId IdType="pubmed">29524936</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond M.F., Sculpher M.J., Claxton K., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes. fourth ed. Oxford University Press; Oxford: 2015.</Citation></Reference><Reference><Citation>Tsuzuki S., Baguelin M., Pebody R., van Leeuwen E. Modelling the optimal target age group for seasonal influenza vaccination in Japan. Vaccine. 2020;38:752&#x2013;762. doi: 10.1016/j.vaccine.2019.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.11.001</ArticleId><ArticleId IdType="pubmed">31735503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Schwehm M., Eichner M. Simulation studies to assess the long-term effects of Japan&#x2019;s change from trivalent to quadrivalent influenza vaccination. Vaccine. 2018;36:624&#x2013;630. doi: 10.1016/j.vaccine.2017.12.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.12.058</ArticleId><ArticleId IdType="pubmed">29292176</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing 2018.</Citation></Reference><Reference><Citation>Briggs A.H., Goldstein D.A., Kirwin E., Meacock R., Pandya A., Vanness D.J., et al. Estimating (quality&#x2010;adjusted) life&#x2010;year losses associated with deaths: with application to COVID&#x2010;19. Health Econ. 2021;30:699&#x2013;707. doi: 10.1002/hec.4208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.4208</ArticleId><ArticleId IdType="pubmed">33368853</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiroiwa T., Noto S., Fukuda T. Japanese population norms of EQ-5D&#x2013;5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24:1193&#x2013;1202. doi: 10.1016/j.jval.2021.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.03.010</ArticleId><ArticleId IdType="pubmed">34372985</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji K., Akiyama T., Tsuzuki S., Matsunaga N., Asai Y., Suzuki S., et al. Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period. J Infect Chemother. 2022;28:1531&#x2013;1535. doi: 10.1016/j.jiac.2022.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.08.004</ArticleId><ArticleId IdType="pmc">PMC9364725</ArticleId><ArticleId IdType="pubmed">35963599</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji K., Akiyama T., Tsuzuki S., Matsunaga N., Asai Y., Suzuki S., et al. Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan. J Infect Chemother. 2022;28:591&#x2013;594. doi: 10.1016/j.jiac.2022.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.01.009</ArticleId><ArticleId IdType="pmc">PMC8769918</ArticleId><ArticleId IdType="pubmed">35074258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcdonald S.A., Lagerweij G.R., De Boer P., De Melker H.E., Pijnacker R., Mughini Gras L., et al. The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years. Eur J Epidemiol. 2022 doi: 10.1007/s10654-022-00895-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-022-00895-0</ArticleId><ArticleId IdType="pmc">PMC9366822</ArticleId><ArticleId IdType="pubmed">35951278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyper G.M.A., Fletcher E., Grant I., Mccartney G., Fischbacher C., Harding O., et al. Measuring disability-adjusted life years (DALYs) due to COVID-19 in Scotland, 2020. Archives of Public Health 2022;80. https://doi.org/10.1186/s13690&#x2013;022-00862-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8972687</ArticleId><ArticleId IdType="pubmed">35365228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri S., Calleja N., Devleesschauwer B., Wyper G.M.A. Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year. BMC Public Health. 2021:21. doi: 10.1186/s12889-021-11893-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11893-4</ArticleId><ArticleId IdType="pmc">PMC8501913</ArticleId><ArticleId IdType="pubmed">34627228</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommel A., von der Lippe E., Plass D., Ziese T., Diercke M., an der Heiden M., et al. The COVID-19 Disease Burden in Germany in 2020. Dtsch Arztebl International 2021;118:145&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212397</ArticleId><ArticleId IdType="pubmed">33958032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires S.M., Redondo H.G., Espenhain L., Jakobsen L.S., Legarth R., Meaidi M., et al. Disability adjusted life years associated with COVID-19 in Denmark in the first year of the pandemic. BMC Public Health. 2022:22. doi: 10.1186/s12889-022-13694-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-13694-9</ArticleId><ArticleId IdType="pmc">PMC9270752</ArticleId><ArticleId IdType="pubmed">35804310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Feng H., Qu J., Luo X., Ma W., Tian J. A systematic review of pharmacoeconomic guidelines. J Med Econ. 2018;21:85&#x2013;96. doi: 10.1080/13696998.2017.1387118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2017.1387118</ArticleId><ArticleId IdType="pubmed">28959910</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technology Assessment Toolkit. IDSI 2017. https://www.idsihealth.org/htatoolkit/ (accessed December 8, 2022).</Citation></Reference><Reference><Citation>World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes, 2nd ed n.d. https://www.who.int/publications-detail-redirect/who-guide-for-standardization-of-economic-evaluations-of-immunization-programmes-2nd-ed (accessed December 8, 2022).</Citation></Reference><Reference><Citation>Eurosurveillance | Estimates of mortality attributable to COVID-19: a statistical model for monitoring COVID-19 and seasonal influenza, Denmark, spring 2020 n.d. https://www.eurosurveillance.org/content/10.2807/1560&#x2013;7917. ES.2021.26.8.2001646 (accessed February 26, 2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7908066</ArticleId><ArticleId IdType="pubmed">33632375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020;20:775. doi: 10.1016/S1473-3099(20)30245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30245-0</ArticleId><ArticleId IdType="pmc">PMC7270796</ArticleId><ArticleId IdType="pubmed">32243813</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor-Barriuso R., P&#xe9;rez-G&#xf3;mez B., Hern&#xe1;n M.A., P&#xe9;rez-Olmeda M., Yotti R., Oteo-Iglesias J., et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. BMJ. 2020;371 doi: 10.1136/bmj.m4509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4509</ArticleId><ArticleId IdType="pmc">PMC7690290</ArticleId><ArticleId IdType="pubmed">33246972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima T., Nomura S., Tanoue Y., Yoneoka D., Eguchi A., Ng C.F.S., et al. Excess All-Cause Deaths during Coronavirus Disease Pandemic, Japan, January&#x2013;May 2020 - Volume 27, Number 3&#x2014;March 2021 - Emerging Infectious Diseases journal - CDC n.d. https://doi.org/10.3201/eid2703.203925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920666</ArticleId><ArticleId IdType="pubmed">33622468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama A., Okada F., Abe K., Imada H., Ouoba S., E.B., et al. A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020. Environ Health Prev Med. 2022;27 doi: 10.1265/ehpm.22-00016. 30&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1265/ehpm.22-00016</ArticleId><ArticleId IdType="pmc">PMC9283912</ArticleId><ArticleId IdType="pubmed">35793938</ArticleId></ArticleIdList></Reference><Reference><Citation>Urashima M., Tanaka E., Ishihara H., Akutsu T. Association between life expectancy at age 60 years before the COVID-19 pandemic and excess mortality during the pandemic in aging countries. JAMA Netw Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.37528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.37528</ArticleId><ArticleId IdType="pmc">PMC9582896</ArticleId><ArticleId IdType="pubmed">36260336</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 2021. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (accessed September 19, 2022).</Citation></Reference><Reference><Citation>Sandmann F.G., Tessier E., Lacy J., Kall M., Van Leeuwen E., Charlett A., et al. Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison W. Clinical Infectious Diseases 2022. https://doi.org/10.1093/cid/ciac151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903473</ArticleId><ArticleId IdType="pubmed">35245941</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol. 2022;94:253&#x2013;262. doi: 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinowska A., Muchlado M., &#x15a;lizie&#x144; Z., Biedunkiewicz B., Heleniak Z., D&#x119;bska-&#x15a;lizie&#x144; A., et al. Post-COVID-19 sydrome and decrease in health-related quality of life in kidney transplant recipients after SARS-COV-2 infection-A cohort longitudinal study from the North of Poland. J Clin Med. 2021;10:5205. doi: 10.3390/jcm10215205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10215205</ArticleId><ArticleId IdType="pmc">PMC8584685</ArticleId><ArticleId IdType="pubmed">34768725</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckenzie L., Shoukat A., Wong K.O., Itahashi K., Yasuda E., Demarsh A., et al. Inferring the true number of SARS-CoV-2 infections in Japan. J Infect Chemother. 2022 doi: 10.1016/j.jiac.2022.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.08.002</ArticleId><ArticleId IdType="pmc">PMC9359925</ArticleId><ArticleId IdType="pubmed">35961504</ArticleId></ArticleIdList></Reference><Reference><Citation>Verelst F., Kuylen E., Beutels P. Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020. Eurosurveillance. 2020;25:2000323. doi: 10.2807/1560-7917.ES.2020.25.13.2000323.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.13.2000323</ArticleId><ArticleId IdType="pmc">PMC7140594</ArticleId><ArticleId IdType="pubmed">32265003</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe R., Kont M.D., Schmit N., Whittaker C., L&#xf8;chen A., Baguelin M., et al. Modelling intensive care unit capacity under different epidemiological scenarios of the COVID-19 pandemic in three Western European countries. Int J Epidemiol. 2021 doi: 10.1093/ije/dyab034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyab034</ArticleId><ArticleId IdType="pmc">PMC8083295</ArticleId><ArticleId IdType="pubmed">33837401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New Engl J Med. 2021;384:1412&#x2013;1423. doi: 10.1056/NEJMoa2101765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101765</ArticleId><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Almukdad S., Ayoub H.H., Altarawneh H.N., Coyle P., Tang P., et al. Covid-19 vaccine protection among children and adolescents in Qatar. New Engl J Med. 2022;387:1865&#x2013;1876. doi: 10.1056/nejmoa2210058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2210058</ArticleId><ArticleId IdType="pmc">PMC9644642</ArticleId><ArticleId IdType="pubmed">36322837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring A.S., Tenforde M.W., Chappell J.D., Gaglani M., Ginde A.A., Mcneal T., et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022 doi: 10.1136/bmj-2021-069761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069761</ArticleId><ArticleId IdType="pmc">PMC8905308</ArticleId><ArticleId IdType="pubmed">35264324</ArticleId></ArticleIdList></Reference><Reference><Citation>Machida M., Wada K. Public health responses to COVID-19 in Japan. Glob Health Med. 2022;4:78&#x2013;82. doi: 10.35772/ghm.2022.01025.</Citation><ArticleIdList><ArticleId IdType="doi">10.35772/ghm.2022.01025</ArticleId><ArticleId IdType="pmc">PMC9066458</ArticleId><ArticleId IdType="pubmed">35586766</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Yoshihara K. The characteristics of influenza-like illness management in Japan. BMC Public Health. 2020;20:568. doi: 10.1186/s12889-020-08603-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-08603-x</ArticleId><ArticleId IdType="pmc">PMC7189553</ArticleId><ArticleId IdType="pubmed">32345248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>